

Table 4(a): PBS processing (excl. Drs Bag) years ending: Jun 2010 to end Jun 2013 - Section 85 Only

Year	Subsidised Prescription Volume	Under co-payment Prescription Volume	Government Cost \$
Year Ending Jun 10	183,579,193	n.a.	7,018,892,155
Year Ending Jun 11	187,804,540	n.a.	7,323,148,803
Year Ending Jun 12	194,548,705	n.a.	7,528,204,119
Year Ending Jun 13	196,953,259	62,019,475	7,069,490,924
<i>Change</i>	2,404,554	n.a.	-458,713,195
<i>%</i>	1.24	n.a.	-6.09

Table 4(b): PBS processing - PBS subsidised and under co-payment prescriptions (incl. Drs Bag) year ending: Jun 2013 - Section 85 Only

	Year Ending Jun 12	Year Ending Jun 13	Change	%
Highest volume drug: Atorvastatin				
Subsidised Prescription Volume	10,507,613	9,611,688	-895,925	-8.53
UCP Prescription Volume	n.a.	176,266	n.a.	n.a.
Government Cost (\$)	593,307,859	422,780,054	-170,527,805	-28.74
Highest Govt cost drug: Atorvastatin				
Subsidised Prescription Volume	10,507,613	9,611,688	-895,925	-8.53
UCP Prescription Volume	n.a.	176,266	n.a.	n.a.
Government Cost (\$)	593,307,859	422,780,054	-170,527,805	-28.74
Highest volume ATC Level 2: LIPID MODIFYING AGENTS				
Subsidised Prescription Volume	25,656,690	25,043,985	-612,705	-2.39
UCP Prescription Volume	n.a.	1,331,068	n.a.	n.a.
Government Cost (\$)	1,330,892,919	1,028,654,443	-302,238,477	-22.71
Highest Government cost ATC Level 2: LIPID MODIFYING AGENTS				
Subsidised Prescription Volume	25,656,690	25,043,985	-612,705	-2.39
UCP Prescription Volume	n.a.	1,331,068	n.a.	n.a.
Government Cost (\$)	1,330,892,919	1,028,654,443	-302,238,477	-22.71
Greatest increase in Govt. cost ATC Level 2: IMMUNOSUPPRESSANTS				
Subsidised Prescription Volume	629,587	708,796	79,209	12.58
UCP Prescription Volume	n.a.	7,941	n.a.	n.a.
Government Cost (\$)	468,457,064	597,465,701	129,008,637	27.54